Physician profile
Benjamin W Quick
NPI 1104211192
$972.37
in general payments reported to CMS, 2019-2025
21 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.46 · 2020: $154 · 2021: $334 · 2022: $192 · 2023: $64.93 · 2024: $23.57 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $203.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $153.71 | 2021-2023 | Mounjaro |
| Novo Nordisk INC | $136.55 | 2020-2024 | Wegovy |
| Abbvie INC. | $91.36 | 2020-2021 | |
| Boston Scientific Corporation | $85.69 | 2022-2025 | Watchman Access System, Watchman Flx |
| Amgen INC. | $78.84 | 2019-2023 | Repatha, Otezla |
| Amarin Pharma, INC. | $73.52 | 2019-2021 | |
| Eisai INC. | $46.64 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $41.20 | 2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $40.13 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.13 | 2021-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $32.11 | 2020-2021 | |
| Astellas Pharma US INC | $28.88 | 2020-2022 | |
| Gilead Sciences, INC. | $26.15 | 2025 | |
| Glaxosmithkline, LLC. | $16.20 | 2021 | |
| Bausch Health US, LLC | $14.05 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $13.34 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.32 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.95 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.88 | 2021 | |
| Esperion Therapeutics, INC. | $11.36 | 2020 | |
| Pfizer INC. | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Quick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.